Ke Li

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jiafei Chen · 2 shared papers, 2020–2026 · strength 0.52
   • Paper Multi-parametric MRI diffusion models combined with clinical information for predicting Ki-67 expression in pancreatic … DOI 10.1007/s00261-025-05164-8↗
   • Paper High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. DOI 10.3892/ol.2019.11205↗
2. Wei Chen · 1 shared paper, 2026 · strength 0.39
   • Paper Multi-parametric MRI diffusion models combined with clinical information for predicting Ki-67 expression in pancreatic … DOI 10.1007/s00261-025-05164-8↗
3. Boyu Qin · 1 shared paper, 2024 · strength 0.19
   • Paper Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cance… DOI 10.1002/cai2.123↗
4. Jing Zhang · 1 shared paper, 2024 · strength 0.19
   • Paper Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cance… DOI 10.1002/cai2.123↗
5. Bo Yeun Yang · 1 shared paper, 2024 · strength 0.19
   • Paper Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cance… DOI 10.1002/cai2.123↗
6. Jiali Yang · 1 shared paper, 2020 · strength 0.13
   • Paper High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. DOI 10.3892/ol.2019.11205↗
7. Wei Chen · 1 shared paper, 2020 · strength 0.13
   • Paper High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. DOI 10.3892/ol.2019.11205↗
8. Zhuoli Zhang · 1 shared paper, 2020 · strength 0.13
   • Paper High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. DOI 10.3892/ol.2019.11205↗
9. Simin Wang · 1 shared paper, 2020 · strength 0.10
   • Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086↗
10. Zhang Li · 1 shared paper, 2020 · strength 0.10
    • Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086↗
11. Chenghao Shao · 1 shared paper, 2020 · strength 0.10
    • Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086↗
12. Yuexiang Wang · 1 shared paper, 2020 · strength 0.10
    • Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086↗
13. Ju‐Feng Wang · 1 shared paper, 2018 · strength 0.10
    • Paper Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic cond… DOI 10.3892/mmr.2018.8932↗
14. Xinfang Hou · 1 shared paper, 2018 · strength 0.10
    • Paper Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic cond… DOI 10.3892/mmr.2018.8932↗
15. Liang Xu · 1 shared paper, 2016 · strength 0.05
    • Paper Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. DOI 10.18632/oncotarget.7336↗
16. Jiayuh Lin · 1 shared paper, 2016 · strength 0.05
    • Paper Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. DOI 10.18632/oncotarget.7336↗
17. Xiaoqing Wu · 1 shared paper, 2016 · strength 0.05
    • Paper Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. DOI 10.18632/oncotarget.7336↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.